| pubmed-article:15136214 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15136214 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15136214 | lifeskim:mentions | umls-concept:C1292778 | lld:lifeskim |
| pubmed-article:15136214 | lifeskim:mentions | umls-concept:C0836924 | lld:lifeskim |
| pubmed-article:15136214 | lifeskim:mentions | umls-concept:C0879626 | lld:lifeskim |
| pubmed-article:15136214 | lifeskim:mentions | umls-concept:C0051809 | lld:lifeskim |
| pubmed-article:15136214 | lifeskim:mentions | umls-concept:C0814225 | lld:lifeskim |
| pubmed-article:15136214 | lifeskim:mentions | umls-concept:C0439234 | lld:lifeskim |
| pubmed-article:15136214 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:15136214 | pubmed:dateCreated | 2004-5-11 | lld:pubmed |
| pubmed-article:15136214 | pubmed:abstractText | Although anagrelide is widely used in the treatment of thrombocythemia in myeloproliferative diseases, there is currently limited information on the efficacy and toxicity of its long-term use. This prospective study investigated clinical toxicity and efficacy of anagrelide during two years of treatment. | lld:pubmed |
| pubmed-article:15136214 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15136214 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15136214 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15136214 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15136214 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15136214 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15136214 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15136214 | pubmed:month | May | lld:pubmed |
| pubmed-article:15136214 | pubmed:issn | 1592-8721 | lld:pubmed |
| pubmed-article:15136214 | pubmed:author | pubmed-author:LärfarsGerdG | lld:pubmed |
| pubmed-article:15136214 | pubmed:author | pubmed-author:BjörkholmMagn... | lld:pubmed |
| pubmed-article:15136214 | pubmed:author | pubmed-author:MauritzsonNil... | lld:pubmed |
| pubmed-article:15136214 | pubmed:author | pubmed-author:MarkevärnBeri... | lld:pubmed |
| pubmed-article:15136214 | pubmed:author | pubmed-author:BirgegårdGunn... | lld:pubmed |
| pubmed-article:15136214 | pubmed:author | pubmed-author:MerupMatsM | lld:pubmed |
| pubmed-article:15136214 | pubmed:author | pubmed-author:LöfvenbergEva... | lld:pubmed |
| pubmed-article:15136214 | pubmed:author | pubmed-author:SamuelssonJan... | lld:pubmed |
| pubmed-article:15136214 | pubmed:author | pubmed-author:PalmbladJanJ | lld:pubmed |
| pubmed-article:15136214 | pubmed:author | pubmed-author:KuttiJackJ | lld:pubmed |
| pubmed-article:15136214 | pubmed:author | pubmed-author:WestinJanJ | lld:pubmed |
| pubmed-article:15136214 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:15136214 | pubmed:volume | 89 | lld:pubmed |
| pubmed-article:15136214 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15136214 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15136214 | pubmed:pagination | 520-7 | lld:pubmed |
| pubmed-article:15136214 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15136214 | pubmed:meshHeading | pubmed-meshheading:15136214... | lld:pubmed |
| pubmed-article:15136214 | pubmed:meshHeading | pubmed-meshheading:15136214... | lld:pubmed |
| pubmed-article:15136214 | pubmed:meshHeading | pubmed-meshheading:15136214... | lld:pubmed |
| pubmed-article:15136214 | pubmed:meshHeading | pubmed-meshheading:15136214... | lld:pubmed |
| pubmed-article:15136214 | pubmed:meshHeading | pubmed-meshheading:15136214... | lld:pubmed |
| pubmed-article:15136214 | pubmed:meshHeading | pubmed-meshheading:15136214... | lld:pubmed |
| pubmed-article:15136214 | pubmed:meshHeading | pubmed-meshheading:15136214... | lld:pubmed |
| pubmed-article:15136214 | pubmed:meshHeading | pubmed-meshheading:15136214... | lld:pubmed |
| pubmed-article:15136214 | pubmed:meshHeading | pubmed-meshheading:15136214... | lld:pubmed |
| pubmed-article:15136214 | pubmed:meshHeading | pubmed-meshheading:15136214... | lld:pubmed |
| pubmed-article:15136214 | pubmed:meshHeading | pubmed-meshheading:15136214... | lld:pubmed |
| pubmed-article:15136214 | pubmed:meshHeading | pubmed-meshheading:15136214... | lld:pubmed |
| pubmed-article:15136214 | pubmed:meshHeading | pubmed-meshheading:15136214... | lld:pubmed |
| pubmed-article:15136214 | pubmed:meshHeading | pubmed-meshheading:15136214... | lld:pubmed |
| pubmed-article:15136214 | pubmed:meshHeading | pubmed-meshheading:15136214... | lld:pubmed |
| pubmed-article:15136214 | pubmed:meshHeading | pubmed-meshheading:15136214... | lld:pubmed |
| pubmed-article:15136214 | pubmed:meshHeading | pubmed-meshheading:15136214... | lld:pubmed |
| pubmed-article:15136214 | pubmed:meshHeading | pubmed-meshheading:15136214... | lld:pubmed |
| pubmed-article:15136214 | pubmed:meshHeading | pubmed-meshheading:15136214... | lld:pubmed |
| pubmed-article:15136214 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15136214 | pubmed:articleTitle | Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. | lld:pubmed |
| pubmed-article:15136214 | pubmed:affiliation | Dept. Int Medicine, University Hospital, Uppsala, Sweden. Gunnar.Birgegard@medsci.uu.se | lld:pubmed |
| pubmed-article:15136214 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15136214 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:15136214 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:15136214 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15136214 | lld:pubmed |
